MarketFriction

IOL Chemicals & Pharmaceuticals Ltd

NSE IOLCP · BSE 524164 · Pharmaceuticals
₹209.39 +1.12%
NSE close2026-10-01
52 week range67.19 - 219.04
Market cap₹5,914 Cr.
P/E33.5
ASM long-term Price band 20% Delivery 30.4%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales545520504502526523528552568580619756
Expenses481476454452484476465490510523527653
Operating Profit6444505142476362575793104
OPM %12%9%10%10%8%9%12%11%10%10%15%14%
Other Income788764577-628
Interest443244443434
Depreciation161616171819192020202021
Profit before tax513238392628454641287187
Tax %26%28%25%24%26%26%30%25%26%25%25%26%
Net Profit382328301921323430215364
EPS in Rs1.290.790.961.010.650.701.081.161.020.701.812.20
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5807119831,6851,8941,9672,1842,2172,1332,0792,3192,524
Expenses5296088631,2761,3211,3751,9271,9901,9011,8772,0492,213
Operating Profit51102120410574592257227232202270310
OPM %9%14%12%24%30%30%12%10%11%10%12%12%
Other Income11610162417253022911
Interest6168645121681616151514
Depreciation303030323639434663728082
Profit before tax-39631336533571223189183138184226
Tax %4%21%12%30%32%22%26%26%26%27%25%
Net Profit-40528237361445166140135101138168
EPS in Rs-1.420.170.998.3212.7015.155.644.774.613.444.695.73
Dividend Payout %0%0%0%0%5%8%14%17%22%23%21%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth15%3%2%19%
Compounded Profit Growth19%-20%2%68%
Stock Price CAGR22%11%28%99%
Return on Equity18%9%8%8%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital485656565757595959595959
Reserves1601291321604177571,2021,3321,4481,5531,6291,740
Borrowings400453447422284593448033117135
Other Liabilities94135182214184297347526434600577653
Total Liabilities7027728178529421,1701,6101,9602,0212,2442,3822,587
Fixed Assets4034003744064124695125617519331,1701,181
CWIP44217271948105901012296
Investments0000001220212121
Other Assets2953694224395036821,0481,2921,1591,1901,1681,289
Total Assets7027728178529421,1701,6101,9602,0212,2442,3822,587
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-47188312027347138091123290179214
Cash from Investing Activity-5-27-23-50-63-184-317-121-119-191-154-198
Cash from Financing Activity509-60-70-197-272-58-2-4-9246-29
Net Cash Flow-2-01-113154-31-0770-13
Free Cash Flow-53-96171213391272-60-8618-3444
CFO/OP-413%34%82%105%83%102%88%60%75%144%97%93%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days315558544352567983819095
Inventory Days27920120110966649895771119591
Days Payable92102115834262799574123112118
Cash Conversion Cycle218154144806755747986697368
Working Capital Days593936234346667172715853
ROCE %-3%4%12%15%56%68%54%18%14%12%9%11%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters48.19%48.19%48.19%48.19%48.19%52.62%52.62%52.62%52.62%52.62%57.48%62.28%
FIIs2.33%2.18%1.40%1.39%1.63%1.49%1.47%2.59%2.25%2.08%1.72%4.87%
DIIs0.35%0.36%0.29%0.09%0.07%0.08%0.07%0.02%0.05%0.03%0.02%0.43%
Public49.12%49.27%50.11%50.34%50.11%45.81%45.84%44.76%45.10%45.26%40.78%32.41%
No. of Shareholders1,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,0401,36,1291,33,5311,31,5501,19,311

Fundamentals

Market Cap₹ 5,914 Cr.
Current Price₹ 201
Stock P/E33.5
Book Value₹ 61.3
ROCE11.3 %
ROE8.42 %
Dividend Yield0.50 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)19%
Compounded Profit Growth (TTM)68%
Standalone figures.
Valuation
Market capRs 6,146 Cr
Enterprise valueRs 6,083 Cr
P/E (TTM)36.53x
Price to book3.42x
Price to sales2.44x
EV / EBITDA18.93x
EV / EBIT25.39x
EV / sales2.41x
Price to cash flow28.66x
Earnings yield2.74%
Dividend yield0.48%
P/E, 3-year average12.14x
P/B, 3-year average0.84x
P/E, 5-year average8.26x
P/B, 5-year average0.61x
Profitability
Operating margin (excl. other income)11.64%
Operating margin (incl. other income)12.04%
EBITDA margin12.73%
Pre-tax margin8.94%
Net profit margin6.67%
Net margin, latest quarter8.53%
ROE7.90%
ROCE10.65%
ROA5.54%
ROE, 3-year average7.57%
ROCE, 3-year average10.60%
ROA, 3-year average5.42%
ROE, 5-year average8.98%
ROCE, 5-year average12.52%
ROA, 5-year average6.51%
ROIC (approx.)10.31%
Tax rate25.33%
Other income / net worth0.52%
Growth
Sales growth (latest year)11.54%
Profit growth (latest year)36.36%
Sales CAGR, 3 years1.51%
Sales CAGR, 5 years3.35%
Profit CAGR, 3 years-0.54%
Profit CAGR, 5 years-20.89%
Sales growth QoQ22.09%
Profit growth QoQ21.25%
Sales growth YoY (latest quarter)37.08%
Profit growth YoY (latest quarter)89.87%
Per share
EPS (TTM)Rs 5.73
EPS (latest year)Rs 4.69
EPS (latest quarter)Rs 2.20
EPS, 3-year averageRs 10.40
EPS, 5-year averageRs 16.65
Book value per shareRs 61.27
Sales per shareRs 85.98
Cash flow per shareRs 7.30
Free cash flow per shareRs 1.50
Dividend per share (latest year)Rs 1.00
Dividend per share, 3-year averageRs 2.27
Dividend per share, 5-year averageRs 2.96
Dividends
Dividend payout21.32%
Dividend payout, 3-year average22.08%
Dividend payout, 5-year average19.44%
Efficiency
Asset turnover0.90x
Fixed asset turnover1.96x
Inventory turnover4.58x
Inventory days80 days
Debtor days95 days
Debtors turnover3.85x
Creditor days118 days
Cash conversion cycle68 days
Working capital days53 days
Leverage
Total debtRs 135 Cr
Cash and bankRs 198 Cr
Net debtRs -63 Cr
Debt to equity0.08x
Net debt / EBITDA-0.20x
Interest coverage17.17x
Current ratio (filing 2026-03-31)1.78x
Quick ratio (filing 2026-03-31)1.24x
Trade payables (filing 2026-03-31)Rs 483 Cr
Owners' fund to total sources69.52%
Debt to assets5.24%
Cash flow
Cash from Operating Activity (latest year)Rs 214 Cr
Cash from Investing Activity (latest year)Rs -198 Cr
Cash from Financing Activity (latest year)Rs -29 Cr
Net Cash Flow (latest year)Rs -13 Cr
Free cash flow (latest year)Rs 44 Cr
FCFE (approx.: FCF + change in debt)Rs 62 Cr
Cash from ops / profit, 5 years1.32x
Sales to cash flow10.82x
Statement figures
Net sales (TTM)Rs 2,524 Cr
Net sales (latest year)Rs 2,319 Cr
Sales (latest quarter)Rs 756 Cr
Operating profit excl. other income (latest year)Rs 270 Cr
Operating profit (latest quarter)Rs 104 Cr
Other income (TTM)Rs 11 Cr
EBITDA (TTM)Rs 321 Cr
PBDT (TTM)Rs 307 Cr
Profit before tax (TTM)Rs 226 Cr
Tax (latest year)Rs 47 Cr
Net profit (TTM)Rs 168 Cr
Net profit (latest year)Rs 138 Cr
Net profit (latest quarter)Rs 64 Cr
Depreciation (TTM)Rs 82 Cr
Depreciation (latest quarter)Rs 21 Cr
Interest (TTM)Rs 14 Cr
Cost of goods sold (latest year)Rs 1,701 Cr
Total expenditure (latest year)Rs 2,049 Cr
Total income (latest year)Rs 2,328 Cr
Share capitalRs 59 Cr
ReservesRs 1,740 Cr
Shareholders' fundsRs 1,798 Cr
Total assetsRs 2,587 Cr
Net blockRs 1,181 Cr
Capital work in progressRs 96 Cr
InvestmentsRs 21 Cr
ReceivablesRs 603 Cr
InventoryRs 371 Cr
Other liabilitiesRs 653 Cr
Shares outstanding (crore)29.35
Ownership
Promoter holding62.28% (+9.66 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 36.5 is at the 84th percentile of its own 9.4-year range (median 17.4, low 4.3, high 128.2).
P/B 3.42 is at the 81th percentile (median 2.14).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodIOLCPNifty 50Difference
1 week+3.0%-2.8% +5.8 pts
1 month+9.9%-6.8% +16.7 pts
3 months+46.5%-7.6% +54.1 pts
6 months+187.7%+0.4% +187.3 pts
1 year+89.1%-9.9% +99.1 pts
2 years+109.4%-13.6% +123.0 pts
3 years+119.6%+14.2% +105.5 pts
5 years+79.5%+27.9% +51.6 pts
3 mutual fund schemes hold about ₹15 Cr. Over three months 1 bought more and 2 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Union Active Momentum Fund2.87%15 +100%
Bandhan BSE Healthcare Index Fund0.14%0 -12%
Motilal Oswal BSE 1000 Index Fund0.01%0 -6%

Red flags

F-score 7 of 8
lookOn NSE surveillance On NSE surveillance: ASM long-term
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹756 Cr +37.0% vs Jun 2025. Net profit ₹64 Cr +88.2%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-02-17Interim Dividend - Re 1 Per Share
2025-03-11Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share0.2000
2025-02-18Interim Dividend - Rs 4 Per Share
2024-08-16Annual General Meeting
2024-02-16Interim Dividend - Rs 5 Per Share
2023-08-03Annual General Meeting
2023-02-17Interim Dividend - Rs 4 Per Share
2022-08-18Annual General Meeting
2022-02-15Interim Dividend - Rs 4 Per Share
2021-09-08 Annual General Meeting/Dividend - Rs 2 Per Share
2020-11-17 Interim Dividend - Rs 4 Per Share
2020-09-17 Annual General Meeting
2020-03-18 Interim Dividend - Rs 3 Per Share
2019-08-21 Annual General Meeting
2018-09-19 Annual General Meeting
2017-09-19 Annual General Meeting
2016-09-19 Annual General Meeting
2015-09-18 Annual General Meeting
2014-09-19Annual General Meeting
2013-09-20Annual General Meeting
2012-09-21Annual General Meeting
2011-09-16Annual General Meeting
DateTypeWhat it says
2026-09-25Granting/withdrawal/surrendeGranting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
2026-09-23Granting/withdrawal/surrendeEU-REACH Registration for Triacetin
2026-09-23Concall / analyst meetSchedule of meet
2026-09-23Concall / analyst meetSchedule of meet
2026-09-21General UpdatesDispatch of Reminder letter to shareholders to update KYC
2026-09-17Concall / analyst meetTranscript
2026-09-11Concall / analyst meetLink of Recording
2026-09-10Concall / analyst meetSchedule of meet
2026-09-09General UpdatesGeneral Updates
2026-09-02Shareholder meetingSubmission of Voting Results along with Scrutinizer s Report with regard to the 39th Annual General Meeting of the Company
2026-09-02Shareholder meetingProceedings of Annual General Meeting held on September 02, 2026
2026-08-26Concall / analyst meetSchedule of meet
2026-08-20Concall / analyst meetTranscript
2026-08-13Concall / analyst meetLink of Recording
2026-08-12Investor PresentationInvestor Presentation
2026-08-10Press ReleaseA press release dated August 10, 2026, titled "Press Release Financial Results for the quarter ended 30th June 2026".
2026-08-10Board meeting outcomeIOL Chemicals and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-07Concall / analyst meetSchedule of meet
2026-08-07Shareholder meetingNotice of Annual General Meeting to be held on September 02, 2026
2026-07-14General UpdatesGeneral Updates
2026-07-01Credit RatingCredit Rating
2026-06-11General UpdatesGeneral Updates
2026-06-10General UpdatesGeneral Updates
2026-06-05Disclosure under SEBI TakeovVarinder Gupta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Ac...
2026-05-28Concall / analyst meetTranscript
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Long Term Additional Surveillance Measure (Long Term ASM): stage 1
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03